AstraZeneca's Tozorakimab Receives FDA Priority Review for COPD After Positive Phase III Results

AstraZeneca announced positive Phase III data for tozorakimab, an investigational anti-IL-33 monoclonal antibody, demonstrating statistically significant reductions in moderate-to-severe exacerbations in chronic obstructive pulmonary disease (COPD) patients. The U.S. Food and Drug Administration (FDA) has granted priority review for the drug, with a regulatory decision anticipated in the first quarter of 2027.